In a groundbreaking review that challenges longstanding assumptions about soil remediation, scientists are turning their focus to the biovolatilization and…
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival (OS)…